| Year |
Citation |
Score |
| 2018 |
Merigan TC. Role of Physician-Scientists in the Control of Human Immunodeficiency Virus. The Journal of Infectious Diseases. 218: S3-S6. PMID 30124973 DOI: 10.1093/Infdis/Jiy089 |
0.382 |
|
| 2012 |
Rath BA, Olshen RA, Halpern J, Merigan TC. Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance. Viruses. 4: 1212-34. PMID 23012621 DOI: 10.3390/V4081212 |
0.318 |
|
| 2009 |
Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nature Medicine. 15: 285-92. PMID 19219022 DOI: 10.1038/Nm.1932 |
0.356 |
|
| 2005 |
Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD. Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 49: 3558-61. PMID 16048984 DOI: 10.1128/Aac.49.8.3558-3561.2005 |
0.39 |
|
| 2005 |
Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 41: 236-42. PMID 15983922 DOI: 10.1086/430709 |
0.394 |
|
| 2005 |
Winters MA, Merigan TC. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms. Antimicrobial Agents and Chemotherapy. 49: 2575-82. PMID 15980322 DOI: 10.1128/Aac.49.7.2575-2582.2005 |
0.385 |
|
| 2005 |
Shulman NS, Delgado J, Bosch RJ, Winters MA, Johnston E, Shafer RW, Katzenstein DA, Merigan TC. Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays. Journal of Acquired Immune Deficiency Syndromes (1999). 39: 78-81. PMID 15851917 DOI: 10.1097/01.Qai.0000159517.78100.7B |
0.327 |
|
| 2004 |
Al Dhahry SH, Scrimgeour EM, Al Suwaid AR, Al Lawati MR, El Khatim HS, Al Kobaisi MF, Merigan TC. Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations. Aids Research and Human Retroviruses. 20: 1166-72. PMID 15588338 DOI: 10.1089/Aid.2004.20.1166 |
0.34 |
|
| 2004 |
Johnston E, Winters MA, Rhee SY, Merigan TC, Schiffer CA, Shafer RW. Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. Antimicrobial Agents and Chemotherapy. 48: 4864-8. PMID 15561868 DOI: 10.1128/Aac.48.12.4864-4868.2004 |
0.317 |
|
| 2004 |
Kagan R, Winters M, Merigan T, Heseltine P. HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. Aids Research and Human Retroviruses. 20: 1-9. PMID 15000693 DOI: 10.1089/088922204322749440 |
0.301 |
|
| 2004 |
Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. The Journal of Infectious Diseases. 189: 1075-83. PMID 14999611 DOI: 10.1086/381707 |
0.356 |
|
| 2004 |
Logsdon BC, Vickrey JF, Martin P, Proteasa G, Koepke JI, Terlecky SR, Wawrzak Z, Winters MA, Merigan TC, Kovari LC. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. Journal of Virology. 78: 3123-32. PMID 14990731 DOI: 10.1128/Jvi.78.6.3123-3132.2004 |
0.302 |
|
| 2003 |
Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O'Neil D, Bancroft L, Al-Harthi L, Jacobson MA, ... Merigan TC, et al. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. The Journal of Infectious Diseases. 188: 1804-14. PMID 14673758 DOI: 10.1086/379899 |
0.382 |
|
| 2003 |
Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, ... ... Merigan TC, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. The New England Journal of Medicine. 349: 2304-15. PMID 14668456 DOI: 10.1056/Nejmoa030265 |
0.315 |
|
| 2003 |
Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, ... ... Merigan TC, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. The New England Journal of Medicine. 349: 2293-303. PMID 14668455 DOI: 10.1056/Nejmoa030264 |
0.365 |
|
| 2003 |
Vickrey JF, Logsdon BC, Proteasa G, Palmer S, Winters MA, Merigan TC, Kovari LC. HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization. Protein Expression and Purification. 28: 165-72. PMID 12651121 DOI: 10.1016/S1046-5928(02)00650-2 |
0.314 |
|
| 2002 |
Lobato RL, Kim EY, Kagan RM, Merigan TC. Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase. Aids Research and Human Retroviruses. 18: 733-6. PMID 12167282 DOI: 10.1089/088922202760072375 |
0.33 |
|
| 2001 |
Kundu-Raychaudhuri S, Sevin A, Kilgo P, Nokta M, Pollard RB, Merigan TC. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946). Aids Research and Human Retroviruses. 17: 1371-8. PMID 11679149 DOI: 10.1089/088922201753197033 |
0.342 |
|
| 2001 |
Kim EY, Winters MA, Kagan RM, Merigan TC. Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients. Journal of Virology. 75: 11227-33. PMID 11602763 DOI: 10.1128/Jvi.75.22.11227-11233.2001 |
0.332 |
|
| 2001 |
Winters MA, Merigan TC. Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs. Antimicrobial Agents and Chemotherapy. 45: 2276-9. PMID 11451685 DOI: 10.1128/Aac.45.8.2276-2279.2001 |
0.329 |
|
| 2001 |
Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, Merigan TC, Harrigan R, Larder BA. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. Journal of Clinical Microbiology. 39: 1522-9. PMID 11283081 DOI: 10.1128/Jcm.39.4.1522-1529.2001 |
0.325 |
|
| 2001 |
Kim EY, Vrang L, Oberg B, Merigan TC. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants. Aids Research and Human Retroviruses. 17: 401-7. PMID 11282008 DOI: 10.1089/088922201750102445 |
0.348 |
|
| 2000 |
Shapero MH, Kundu SK, Engleman E, Laus R, Van Schooten WCA, Merigan TC. In Vivo Persistence of Donor Cells following Adoptive Transfer of Allogeneic Dendritic Cells in HIV-Infected Patients. Cell Transplantation. 9: 307-317. PMID 28880658 DOI: 10.1177/096368970000900302 |
0.368 |
|
| 2000 |
Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, et al. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. The Journal of Infectious Diseases. 182: 1357-64. PMID 11023459 DOI: 10.1086/315860 |
0.36 |
|
| 2000 |
Gray CM, Lawrence J, Ranheim EA, Vierra M, Zupancic M, Winters M, Altman J, Montoya J, Zolopa A, Schapiro J, Haase AT, Merigan TC. Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells. Aids Research and Human Retroviruses. 16: 1357-69. PMID 11018855 DOI: 10.1089/08892220050140900 |
0.315 |
|
| 1999 |
Katzenstein DA, Kundu S, Spritzler J, Smoller BR, Haszlett P, Valentine F, Merigan TC. Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen. Journal of Acquired Immune Deficiency Syndromes (1999). 22: 341-7. PMID 10634195 DOI: 10.1097/00126334-199912010-00004 |
0.335 |
|
| 1999 |
Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Annals of Internal Medicine. 131: 813-21. PMID 10610625 DOI: 10.7326/0003-4819-131-11-199912070-00003 |
0.317 |
|
| 1999 |
Palmer S, Shafer RW, Merigan TC. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Antimicrobial Agents and Chemotherapy. 43: 2046-50. PMID 10428934 DOI: 10.1128/Aac.43.8.2046 |
0.338 |
|
| 1999 |
Palmer S, Shafer RW, Merigan TC. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. Aids (London, England). 13: 661-7. PMID 10397560 DOI: 10.1097/00002030-199904160-00006 |
0.316 |
|
| 1999 |
Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, Efron B, Winslow D, Merigan TC. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. The Journal of Infectious Diseases. 179: 1356-64. PMID 10228055 DOI: 10.1086/314751 |
0.366 |
|
| 1999 |
Schapiro JM, Winters MA, Lawrence J, Merigan TC. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. Aids (London, England). 13: 359-65. PMID 10199226 DOI: 10.1097/00002030-199902250-00008 |
0.368 |
|
| 1999 |
Kleim JP, Winters M, Dunkler A, Suarez JR, Riess G, Winkler I, Balzarini J, Oette D, Merigan TC. Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group. The Journal of Infectious Diseases. 179: 709-13. PMID 9952383 DOI: 10.1086/314633 |
0.421 |
|
| 1999 |
Schapiro JM, Lawrence J, Speck R, Winters MA, Efron B, Coombs RW, Collier AC, Merigan TC. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. The Journal of Infectious Diseases. 179: 249-53. PMID 9841849 DOI: 10.1086/314541 |
0.317 |
|
| 1998 |
Merigan TC. Use of PCR to measure HIV viral changes in drug-resistant genes in genital fluids. Journal of Reproductive Immunology. 41: 177-85. PMID 10213309 DOI: 10.1016/S0165-0378(98)00057-6 |
0.393 |
|
| 1998 |
Kundu SK, Dupuis M, Sette A, Celis E, Dorner F, Eibl M, Merigan TC. Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization. Aids Research and Human Retroviruses. 14: 1669-78. PMID 9870321 DOI: 10.1089/Aid.1998.14.1669 |
0.352 |
|
| 1998 |
Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, Katzenstein DA, Merigan TC. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. The Journal of Clinical Investigation. 102: 1769-75. PMID 9819361 DOI: 10.1172/Jci4948 |
0.328 |
|
| 1998 |
Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Annals of Internal Medicine. 128: 906-11. PMID 9634429 DOI: 10.7326/0003-4819-128-11-199806010-00008 |
0.313 |
|
| 1998 |
Gray CM, Schapiro JM, Winters MA, Merigan TC. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. Aids Research and Human Retroviruses. 14: 561-9. PMID 9591710 DOI: 10.1089/Aid.1998.14.561 |
0.348 |
|
| 1998 |
Kundu SK, Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC, Eibl M, Merigan TC. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. Aids Research and Human Retroviruses. 14: 551-60. PMID 9591709 DOI: 10.1089/Aid.1998.14.551 |
0.356 |
|
| 1998 |
Winters MA, Schapiro JM, Lawrence J, Merigan TC. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. Journal of Virology. 72: 5303-6. PMID 9573309 DOI: 10.1128/Jvi.72.6.5303-5306.1998 |
0.322 |
|
| 1998 |
Zipeto D, Hong C, Gerna G, Zavattoni M, Katzenstein D, Merigan TC, Rasmussen L. Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients. Aids Research and Human Retroviruses. 14: 533-6. PMID 9566556 DOI: 10.1089/Aid.1998.14.533 |
0.301 |
|
| 1998 |
Rey D, Hughes M, Pi JT, Winters M, Merigan TC, Katzenstein DA. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association. 17: 203-8. PMID 9495218 DOI: 10.1097/00042560-199803010-00003 |
0.378 |
|
| 1998 |
Schapiro JM, Winters MA, Vierra M, Crawford S, Merigan TC. Lymph node human immunodeficiency virus RNA levels and resistance mutations in patients receiving high-dose saquinavir. The Journal of Infectious Diseases. 177: 477-80. PMID 9466542 DOI: 10.1086/517380 |
0.312 |
|
| 1997 |
Rasmussen L, Zipeto D, Wolitz RA, Dowling A, Efron B, Merigan TC. Risk for retinitis in patients with AIDS can be assessed by quantitation of threshold levels of cytomegalovirus DNA burden in blood. The Journal of Infectious Diseases. 176: 1146-55. PMID 9359712 DOI: 10.1086/514106 |
0.332 |
|
| 1997 |
Kundu SK, Katzenstein D, Valentine FT, Spino C, Efron B, Merigan TC. Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association. 15: 269-74. PMID 9292585 DOI: 10.1097/00042560-199708010-00004 |
0.352 |
|
| 1997 |
Kundu SK, Merigan TC. Heterogeneity of cytokine functions in HIV infection. Immunology. 91: 234-8. PMID 9227322 DOI: 10.1046/J.1365-2567.1997.00247.X |
0.353 |
|
| 1997 |
Shafer RW, Eisen JA, Merigan TC, Katzenstein DA. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. Journal of Virology. 71: 5441-8. PMID 9188616 DOI: 10.1128/Jvi.71.7.5441-5448.1997 |
0.302 |
|
| 1997 |
Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrobial Agents and Chemotherapy. 41: 757-62. PMID 9087484 DOI: 10.1128/Aac.41.4.757 |
0.395 |
|
| 1997 |
Jellinger RM, Shafer RW, Merigan TC. A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates. The Journal of Infectious Diseases. 175: 561-6. PMID 9041326 DOI: 10.1093/Infdis/175.3.561 |
0.34 |
|
| 1997 |
Shafer RW, Levee DJ, Winters MA, Richmond KL, Huang D, Merigan TC. Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. Journal of Clinical Microbiology. 35: 520-2. PMID 9003633 DOI: 10.1128/Jcm.35.2.520-522.1997 |
0.35 |
|
| 1997 |
Dupuis M, Peshwa MV, Benike C, Kundu SK, Engleman EG, Van Schooten WC, Merigan TC. Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals. Aids Research and Human Retroviruses. 13: 33-9. PMID 8989425 DOI: 10.1089/Aid.1997.13.33 |
0.346 |
|
| 1997 |
Rasmussen L, Hong C, Zipeto D, Morris S, Sherman D, Chou S, Miner R, Drew WL, Wolitz R, Dowling A, Warford A, Merigan TC. Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients. The Journal of Infectious Diseases. 175: 179-84. PMID 8985216 DOI: 10.1093/Infdis/175.1.179 |
0.388 |
|
| 1996 |
Shafer RW, Winters MA, Iversen AK, Merigan TC. Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 40: 2887-90. PMID 9124861 DOI: 10.1128/Aac.40.12.2887 |
0.326 |
|
| 1996 |
Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. Jama. 276: 1955-6. PMID 8971062 DOI: 10.1001/Jama.1996.03540240033024 |
0.374 |
|
| 1996 |
Holodniy M, Katzenstein D, Mole L, Winters M, Merigan T. Human Immunodeficiency Virus Reverse Transcriptase Codon 215 Mutations Diminish Virologic Response to Didanosine-Zidovudine Therapy in Subjects with Non-Syncytium-Inducing Phenotype The Journal of Infectious Diseases. 174: 854-857. PMID 8843229 DOI: 10.1093/Infdis/174.4.854 |
0.334 |
|
| 1996 |
Merigan TC, Hirsch RL, Fisher AC, Meyerson LA, Goldstein G, Winters MA. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin. Aids (London, England). 10: 159-65. PMID 8838703 DOI: 10.1097/00002030-199602000-00005 |
0.341 |
|
| 1996 |
Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. The New England Journal of Medicine. 335: 1091-8. PMID 8813039 DOI: 10.1056/Nejm199610103351502 |
0.377 |
|
| 1996 |
Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. The New England Journal of Medicine. 335: 1081-90. PMID 8813038 DOI: 10.1056/Nejm199610103351501 |
0.365 |
|
| 1996 |
Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, Gingeras TR. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Medicine. 2: 753-9. PMID 8673920 DOI: 10.1038/Nm0796-753 |
0.348 |
|
| 1996 |
Valentine FT, Kundu S, Haslett PA, Katzenstein D, Beckett L, Spino C, Borucki M, Vasquez M, Smith G, Korvick J, Kagan J, Merigan TC. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). The Journal of Infectious Diseases. 173: 1336-46. PMID 8648205 DOI: 10.1093/Infdis/173.6.1336 |
0.376 |
|
| 1996 |
Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Annals of Internal Medicine. 124: 1039-50. PMID 8633817 DOI: 10.7326/0003-4819-124-12-199606150-00003 |
0.386 |
|
| 1996 |
Ramachandran R, Katzenstein DA, Winters MA, Kundu SK, Merigan TC. Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. The Journal of Infectious Diseases. 173: 1005-8. PMID 8603940 DOI: 10.1093/Infdis/173.4.1005 |
0.322 |
|
| 1996 |
Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. The New England Journal of Medicine. 334: 1011-7. PMID 8598838 DOI: 10.1056/Nejm199604183341602 |
0.408 |
|
| 1996 |
Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, Merigan TC. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. Journal of Virology. 70: 1086-90. PMID 8551567 DOI: 10.1128/Jvi.70.2.1086-1090.1996 |
0.336 |
|
| 1996 |
Dwyer DE, Cunningham AL, Adelstein S, Merigan TC. 4.3 The laboratory in managing HIV infection The Medical Journal of Australia. 164: 301-303. DOI: 10.5694/J.1326-5377.1996.Tb94197.X |
0.313 |
|
| 1995 |
Wagner JA, Ross H, Hunt S, Gamberg P, Valantine H, Merigan TC, Stinson EB. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation. 60: 1473-7. PMID 8545877 DOI: 10.1097/00007890-199560120-00018 |
0.333 |
|
| 1995 |
Rasmussen L, Morris S, Hamed K, Merigan TC. Human cytomegalovirus DNA is present in CD45+ cells in semen from human immunodeficiency virus-infected patients. The Journal of Infectious Diseases. 171: 432-6. PMID 7844383 DOI: 10.1093/Infdis/171.2.432 |
0.396 |
|
| 1995 |
Rasmussen L, Morris S, Zipeto D, Fessel J, Wolitz R, Dowling A, Merigan TC. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. The Journal of Infectious Diseases. 171: 177-82. PMID 7798658 DOI: 10.1093/Infdis/171.1.177 |
0.375 |
|
| 1995 |
Shafer RW, Merigan TC. New virologic tools for the design and analysis of clinical trials. The Journal of Infectious Diseases. 171: 1325-8. PMID 7751711 DOI: 10.1093/Infdis/171.5.1325 |
0.362 |
|
| 1995 |
Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. Clarification of a method to reverse transcribe human immunodeficiency virus RNA. The Journal of Infectious Diseases. 171: 1072. PMID 7706796 DOI: 10.1093/Infdis/171.4.1072 |
0.309 |
|
| 1995 |
Shafer RW, Aguiniga E, Merigan TC. Quantitative analysis of syncytium-inducing and non-syncytium-inducing virus in patients infected with human immunodeficiency virus type 1. Journal of Clinical Microbiology. 33: 212-4. PMID 7699044 DOI: 10.1128/Jcm.33.1.212-214.1995 |
0.379 |
|
| 1995 |
Iversen AK, Shpaer EG, Rodrigo AG, Hirsch MS, Walker BD, Sheppard HW, Merigan TC, Mullins JI. Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. Journal of Virology. 69: 5743-53. PMID 7637019 DOI: 10.1128/Jvi.69.9.5743-5753.1995 |
0.395 |
|
| 1995 |
Collier AC, Coombs RW, Katzenstein D, Holodniy M, Gibson J, Mordenti J, Izu AE, Duliege AM, Ammann AJ, Merigan T, Corey L. Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 10: 150-156. PMID 7552478 DOI: 10.1097/00042560-199510020-00006 |
0.317 |
|
| 1995 |
Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. The Journal of Infectious Diseases. 172: 70-8. PMID 7541064 DOI: 10.1093/Infdis/172.1.70 |
0.388 |
|
| 1995 |
Merigan TC. A quarter-century of antiviral therapy. The New England Journal of Medicine. 333: 1704-5. PMID 7477225 DOI: 10.1056/Nejm199512213332509 |
0.343 |
|
| 1995 |
Tierney M, Pottage J, Kessler H, Fischl M, Richman D, Merigan T, Powderly W, Smith S, Karim A, Sherman J. The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100) Journal of Acquired Immune Deficiency Syndromes. 10: 549-553. DOI: 10.1097/00042560-199510050-00008 |
0.363 |
|
| 1995 |
Merigan T. Individualization of therapy using viral markers. Journal of Acquired Immune Deficiency Syndromes. 10. DOI: 10.1097/00042560-199510001-00009 |
0.394 |
|
| 1994 |
Ho RJ, Burke RL, Merigan TC. Disposition of antigen-presenting liposomes in vivo: effect on presentation of herpes simplex virus antigen rgD. Vaccine. 12: 235-42. PMID 8165856 DOI: 10.1016/0264-410X(94)90200-3 |
0.31 |
|
| 1994 |
Shafer RW, Kozal MJ, Winters MA, Iversen AKN, Katzenstein DA, Ragni MV, Meyer WA, Gupta P, Rasheed S, Coombs R, Katzman M, Fiscus S, Merigan TC. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations Journal of Infectious Diseases. 169: 722-729. PMID 8133086 DOI: 10.1093/Infdis/169.4.722 |
0.345 |
|
| 1994 |
Kroodsma KL, Kozal MJ, Hamed KA, Winters MA, Merigan TC. Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. The Journal of Infectious Diseases. 170: 1292-5. PMID 7963730 DOI: 10.1093/Infdis/170.5.1292 |
0.387 |
|
| 1994 |
Liu M, Fahey JL, Aziz N, Cumberland WG, Skowron G, Merigan T. Zidovudine and dideoxycytidine differ in their effects on human immunodeficiency virus-induced pathologic activation of the immune system Journal of Infectious Diseases. 170: 1165-1171. PMID 7963709 DOI: 10.1093/Infdis/170.5.1165 |
0.385 |
|
| 1994 |
Ramachandran RV, Katzenstein D, Merigan TC. Long-term effects of interleukin-2 on CD4 cell counts in human immunodeficiency virus-infected patients. The Journal of Infectious Diseases. 170: 1044-6. PMID 7930706 DOI: 10.1093/Infdis/170.4.1044 |
0.364 |
|
| 1994 |
Ramachandran RV, Katzenstein DA, Wood R, Batts DH, Merigan TC. Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. The Journal of Infectious Diseases. 170: 1009-13. PMID 7930696 DOI: 10.1093/Infdis/170.4.1009 |
0.363 |
|
| 1994 |
Rasmussen L, Morris S, Wolitz R, Dowling A, Fessell J, Holodniy M, Merigan TC. Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. The Journal of Infectious Diseases. 170: 673-7. PMID 7915750 DOI: 10.1093/Infdis/170.3.673 |
0.392 |
|
| 1994 |
Katzenstein DA, Winters M, Bubp J, Israelski D, Winger E, Merigan TC. Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. The Journal of Infectious Diseases. 169: 416-9. PMID 7906292 DOI: 10.1093/Infdis/169.2.416 |
0.347 |
|
| 1994 |
Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Annals of Internal Medicine. 121: 263-8. PMID 7518658 DOI: 10.7326/0003-4819-121-4-199408150-00005 |
0.382 |
|
| 1994 |
Merigan TC. Viral Response Driven Antiretroviral Therapy Aids. 8. DOI: 10.1097/00002030-199411004-00003 |
0.302 |
|
| 1994 |
Kozal MJ, Merigan TC. Therapy of HIV-1 infection Current Opinion in Infectious Diseases. 7: 72-81. DOI: 10.1097/00001432-199402000-00013 |
0.332 |
|
| 1993 |
Hamed KA, Winters MA, Holodniy M, Katzenstein DA, Merigan TC. Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. The Journal of Infectious Diseases. 167: 798-802. PMID 8450243 DOI: 10.1093/Infdis/167.4.798 |
0.359 |
|
| 1993 |
Berger AR, Arezzo JC, Schaumburg HH, Skowron G, Merigan T, Bozzette S, Richman D, Soo W. 2′,3′-Dideoxycytidine (ddC) toxic neuropathy: A study of 52 patients Neurology. 43: 358-362. PMID 8382349 DOI: 10.1212/Wnl.43.2.358 |
0.31 |
|
| 1993 |
Winters MA, Merigan TC. Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells. Aids Research and Human Retroviruses. 9: 1091-6. PMID 8312052 DOI: 10.1089/Aid.1993.9.1091 |
0.32 |
|
| 1993 |
Shafer RW, Kozal MJ, Katzenstein DA, Lipil WH, Johnstone IF, Merigan TC. Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates. Journal of Virological Methods. 41: 297-310. PMID 8097199 DOI: 10.1016/0166-0934(93)90019-N |
0.326 |
|
| 1993 |
Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. The Journal of Infectious Diseases. 167: 519-25. PMID 8095058 DOI: 10.1093/Infdis/167.3.519 |
0.353 |
|
| 1993 |
Skowron G, Bozzette SA, Lim L, Pettinelli CB, Schaumburg HH, Arezzo J, Fischl MA, Powderly WG, Gocke DJ, Richman DD, Pottage JC, Antoniskis D, McKinley GF, Hyslop NE, Ray G, ... ... Merigan TC, et al. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Annals of Internal Medicine. 118: 321-30. PMID 8094279 DOI: 10.7326/0003-4819-118-5-199303010-00001 |
0.302 |
|
| 1993 |
Winters MA, Tan LB, Katzenstein DA, Merigan TC. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. Journal of Clinical Microbiology. 31: 2960-6. PMID 7903317 DOI: 10.1128/Jcm.31.11.2960-2966.1993 |
0.33 |
|
| 1993 |
Montoya JG, Wood R, Katzenstein D, Holodny M, Merigan TC. Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect. Journal of Clinical Microbiology. 31: 2692-6. PMID 7902845 DOI: 10.1128/Jcm.31.10.2692-2696.1993 |
0.349 |
|
| 1993 |
Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. The Journal of Infectious Diseases. 167: 526-32. PMID 7680058 DOI: 10.1093/Infdis/167.3.526 |
0.359 |
|
| 1993 |
Merigan TC. Combination Anti-HIV Therapy: Questions and Answers Journal of Acquired Immune Deficiency Syndromes. 6: 225-228. DOI: 10.1007/978-1-4615-2964-4_27 |
0.396 |
|
| 1992 |
Ho RJ, Burke RL, Merigan TC. Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs. Vaccine. 10: 209-13. PMID 1561827 DOI: 10.1016/0264-410X(92)90153-B |
0.302 |
|
| 1992 |
Winters MA, Holodniy M, Katzenstein DA, Merigan TC. Quantitative RNA and DNA gene amplification can rapidly monitor HIV infection and antiviral activity in cell cultures. Pcr Methods and Applications. 1: 257-62. PMID 1477661 DOI: 10.1101/Gr.1.4.257 |
0.393 |
|
| 1992 |
Kundu SK, Katzenstein D, Moses LE, Merigan TC. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proceedings of the National Academy of Sciences of the United States of America. 89: 11204-8. PMID 1360665 DOI: 10.1073/Pnas.89.23.11204 |
0.342 |
|
| 1992 |
Kundu SK, Merigan TC. Equivalent recognition of HIV proteins, Env, Gag and Pol, by CD4+ and CD8+ cytotoxic T-lymphocytes. Aids (London, England). 6: 643-9. PMID 1354446 DOI: 10.1097/00002030-199207000-00005 |
0.325 |
|
| 1992 |
Kundu SK, Merigan TC. CD8+ CD11+ suppressor cells in HIV-infected asymptomatic patients: effect on HIV-specific cytotoxicity. Viral Immunology. 5: 15-25. PMID 1351730 DOI: 10.1089/Vim.1992.5.15 |
0.325 |
|
| 1991 |
Merigan TC, Katzenstein DA. Relation of the pathogenesis of human immunodeficiency virus infection to various strategies for its control. Reviews of Infectious Diseases. 13: 292-302. PMID 2041962 DOI: 10.1093/Clinids/13.2.292 |
0.405 |
|
| 1991 |
Holodniy M, Katzenstein DA, Sengupta S, Wang AM, Casipit C, Schwartz DH, Konrad M, Groves E, Merigan TC. Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. The Journal of Infectious Diseases. 163: 862-6. PMID 2010639 DOI: 10.1086/190.11.2050 |
0.36 |
|
| 1991 |
Davis BR, Schwartz DH, Marx JC, Johnson CE, Berry JM, Lyding J, Merigan TC, Zander A. Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo. Journal of Virology. 65: 1985-90. PMID 2002553 DOI: 10.1128/Jvi.65.4.1985-1990.1991 |
0.364 |
|
| 1991 |
Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC. Inhibition of human immunodeficiency virus gene amplification by heparin. Journal of Clinical Microbiology. 29: 676-9. PMID 1909709 DOI: 10.1128/Jcm.29.4.676-679.1991 |
0.344 |
|
| 1991 |
Merigan TC. Treatment of AIDS with combinations of antiretroviral agents. The American Journal of Medicine. 90: 8S-17S. PMID 1850192 DOI: 10.1016/0002-9343(91)90405-M |
0.383 |
|
| 1991 |
Merigan TC, Amato DA, Balsley J, Power M, Price WA, Benoit S, Perez-Michael A, Brownstein A, Kramer AS, Brettler D. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group. Blood. 78: 900-6. PMID 1831059 DOI: 10.1182/Blood.V78.4.900.Bloodjournal784900 |
0.355 |
|
| 1991 |
Holodniy M, Katzenstein DA, Israelski DM, Merigan TC. Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. The Journal of Clinical Investigation. 88: 1755-9. PMID 1682345 DOI: 10.1172/Jci115494 |
0.314 |
|
| 1991 |
Mermin JH, Holodniy M, Katzenstein DA, Merigan TC. Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. The Journal of Infectious Diseases. 164: 769-72. PMID 1680138 DOI: 10.1093/Infdis/164.4.769 |
0.35 |
|
| 1991 |
Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes. 4: 11-23. PMID 1670586 DOI: 10.1097/00126334-199101000-00002 |
0.329 |
|
| 1991 |
Rasmussen L, Matkin C, Spaete R, Pachl C, Merigan TC. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. The Journal of Infectious Diseases. 164: 835-42. PMID 1658156 DOI: 10.1093/Infdis/164.5.835 |
0.303 |
|
| 1990 |
Ho RJ, Burke RL, Merigan TC. Physical and biological characterization of antigen presenting liposome formulations: relative efficacy for the treatment of recurrent genital HSV-2 in guinea pigs. Antiviral Research. 13: 187-99. PMID 2383000 DOI: 10.1016/0166-3542(90)90037-8 |
0.306 |
|
| 1990 |
Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, Liu S, Byington RE, Henochowicz S, Gubish E. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Annals of Internal Medicine. 112: 247-53. PMID 2297203 DOI: 10.7326/0003-4819-112-4-247 |
0.37 |
|
| 1990 |
Merigan TC, Resta S. Cytomegalovirus: where have we been and where are we going? Reviews of Infectious Diseases. 12: S693-700. PMID 2173098 DOI: 10.1093/Clinids/12.Supplement_7.S693 |
0.373 |
|
| 1990 |
Skowron G, Merigan TC. Alternating and intermittent regimens of zidovudine (3'-azido-3'-deoxythymidine) and dideoxycytidine (2',3'-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. The American Journal of Medicine. 88: 20S-23S. PMID 2159705 DOI: 10.1016/0002-9343(90)90417-C |
0.313 |
|
| 1990 |
Basham T, Rios CD, Holdener T, Merigan TC. Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model. The Journal of Infectious Diseases. 161: 1006-9. PMID 2157768 DOI: 10.1093/Infdis/161.5.1006 |
0.333 |
|
| 1990 |
Fischl MA, Parker CB, Pettinelli C, Wulfsohn M, Hirsch MS, Collier AC, Antoniskis D, Ho M, Richman DD, Fuchs E, Merigan TC, Reichman RC, Gold J, Steigbigel N, Leoung GS, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome New England Journal of Medicine. 323: 1009-1014. PMID 1977079 DOI: 10.1056/Nejm199010113231501 |
0.349 |
|
| 1990 |
Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, Wong B, Merigan TC, McAuliffe VJ, Hyslop NE, Rhame FS, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial Annals of Internal Medicine. 112: 727-737. PMID 1970466 DOI: 10.7326/0003-4819-112-10-727 |
0.374 |
|
| 1989 |
Merigan TC. A personal view of efforts in treatment of human immunodeficiency virus infection in 1988. The Journal of Infectious Diseases. 159: 390-9. PMID 2644377 DOI: 10.1093/Infdis/159.3.390 |
0.362 |
|
| 1989 |
Ho RJ, Burke RL, Merigan TC. Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs. Journal of Virology. 63: 2951-8. PMID 2542605 DOI: 10.1128/Jvi.63.7.2951-2958.1989 |
0.356 |
|
| 1989 |
Merigan TC, Skowron G, Bozzette SA, Richman D, Uttamchandani R, Fischl M, Schooley R, Hirsch M, Soo W, Pettinelli C. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Annals of Internal Medicine. 110: 189-94. PMID 2536257 DOI: 10.7326/0003-4819-110-3-189 |
0.371 |
|
| 1989 |
Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood. 73: 651-61. PMID 2465039 DOI: 10.1182/Blood.V73.3.651.651 |
0.301 |
|
| 1988 |
Bissett J, Eisenberg M, Gregory P, Robinson WS, Merigan TC. Recombinant fibroblast interferon and immune interferon for treating chronic hepatitis B virus infection: patients' tolerance and the effect on viral markers. The Journal of Infectious Diseases. 157: 1076-80. PMID 3129521 DOI: 10.1093/Infdis/157.5.1076 |
0.386 |
|
| 1988 |
Keay S, Petersen E, Icenogle T, Zeluff BJ, Samo T, Busch D, Newman CL, Buhles WC, Merigan TC. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. Reviews of Infectious Diseases. 10: S563-72. PMID 2847294 DOI: 10.1093/Clinids/10.Supplement_3.S563 |
0.306 |
|
| 1988 |
Torseth JW, Berman PW, Merigan TC. Recombinant HIV structural proteins detect specific cellular immunity in vitro in infected individuals. Aids Research and Human Retroviruses. 4: 23-30. PMID 2835070 DOI: 10.1089/Aid.1988.4.23 |
0.412 |
|
| 1988 |
Rasmussen L, Nelson M, Neff M, Merigan TC. Characterization of two different human cytomegalovirus glycoproteins which are targets for virus neutralizing antibody. Virology. 163: 308-18. PMID 2833009 DOI: 10.1016/0042-6822(88)90271-1 |
0.331 |
|
| 1988 |
Keay S, Teng N, Eisenberg M, Story B, Sellers PW, Merigan TC. Topical interferon for treating condyloma acuminata in women. The Journal of Infectious Diseases. 158: 934-9. PMID 2460568 DOI: 10.1093/Infdis/158.5.934 |
0.321 |
|
| 1987 |
Konrad MW, Childs AL, Merigan TC, Borden EC. Assessment of the antigenic response in humans to a recombinant mutant interferon beta. Journal of Clinical Immunology. 7: 365-75. PMID 3308943 DOI: 10.1007/Bf00917014 |
0.326 |
|
| 1987 |
Merigan TC. Is recombinant interleukin-2 the best way to deliver interferon-gamma in human disease? Journal of Interferon Research. 7: 635-9. PMID 3119733 DOI: 10.1089/Jir.1987.7.635 |
0.319 |
|
| 1987 |
Weinberg A, Konrad M, Merigan TC. Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs. Journal of Virology. 61: 2120-7. PMID 3035213 DOI: 10.1128/Jvi.61.7.2120-2127.1987 |
0.382 |
|
| 1987 |
Torseth JW, Cohen GH, Eisenberg RJ, Berman PW, Lasky LA, Cerini CP, Heilman CJ, Kerwar S, Merigan TC. Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte responses. Journal of Virology. 61: 1532-9. PMID 3033279 DOI: 10.1128/Jvi.61.5.1532-1539.1987 |
0.37 |
|
| 1987 |
Keay S, Bissett J, Merigan TC. Ganciclovir treatment of cytomegalovirus infections in iatrogenically immunocompromised patients. The Journal of Infectious Diseases. 156: 1016-21. PMID 2824621 DOI: 10.1093/Infdis/156.6.1016 |
0.323 |
|
| 1987 |
Torseth JW, Nickoloff BJ, Basham TY, Merigan TC. Beta interferon produced by keratinocytes in human cutaneous infection with herpes simplex virus. The Journal of Infectious Diseases. 155: 641-8. PMID 2434580 DOI: 10.1093/Infdis/155.4.641 |
0.389 |
|
| 1986 |
Eisenberg M, Rosno S, Garcia G, Konrad MW, Gregory PB, Robinson WS, Merigan TC. Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection. Antimicrobial Agents and Chemotherapy. 29: 122-6. PMID 3524420 DOI: 10.1128/Aac.29.1.122 |
0.343 |
|
| 1986 |
Torseth JW, Merigan TC. Significance of local gamma interferon in recurrent herpes simplex infection. The Journal of Infectious Diseases. 153: 979-84. PMID 3084668 DOI: 10.1093/Infdis/153.5.979 |
0.307 |
|
| 1986 |
Weinberg A, Rasmussen L, Merigan TC. Acute genital infection in guinea pigs: effect of recombinant interleukin-2 on herpes simplex virus type 2. The Journal of Infectious Diseases. 154: 134-40. PMID 3011918 DOI: 10.1093/Infdis/154.1.134 |
0.338 |
|
| 1986 |
Nickoloff BJ, Basham TY, Merigan TC, Torseth JW, Morhenn VB. Human keratinocyte-lymphocyte reactions in vitro. The Journal of Investigative Dermatology. 87: 11-8. PMID 2941488 DOI: 10.1111/1523-1747.Ep12523513 |
0.305 |
|
| 1985 |
Horning SJ, Merigan TC, Krown SE, Gutterman JU, Louie A, Gallagher J, McCravey J, Abramson J, Cabanillas F, Oettgen H. Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial. Cancer. 56: 1305-10. PMID 4027869 DOI: 10.1002/1097-0142(19850915)56:6<1305::Aid-Cncr2820560614>3.0.Co;2-N |
0.3 |
|
| 1985 |
Cunningham AL, Turner RR, Miller AC, Para MF, Merigan TC. Evolution of recurrent herpes simplex lesions. An immunohistologic study. The Journal of Clinical Investigation. 75: 226-33. PMID 3880773 DOI: 10.1172/Jci111678 |
0.306 |
|
| 1985 |
Cunningham AL, Basham TY, Para MF, Merigan TC. Role of macrophage D-region antigens and T-lymphocyte differentiation antigens in induction of gamma interferon. Journal of Interferon Research. 5: 477-91. PMID 2997338 DOI: 10.1089/Jir.1985.5.477 |
0.304 |
|
| 1985 |
Connors JM, Andiman WA, Howarth CB, Liu E, Merigan TC, Savage ME, Jacobs C. Treatment of nasopharyngeal carcinoma with human leukocyte interferon. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 3: 813-7. PMID 2989445 DOI: 10.1200/Jco.1985.3.6.813 |
0.369 |
|
| 1985 |
Preiksaitis JK, Grumet FC, Smith WK, Merigan TC. Transfusion-acquired cytomegalovirus infection in cardiac surgery patients. Journal of Medical Virology. 15: 283-90. PMID 2984327 DOI: 10.1002/Jmv.1890150309 |
0.33 |
|
| 1985 |
Cunningham AL, Nelson PA, Fathman CG, Merigan TC. Interferon gamma production by herpes simplex virus antigen-specific T cell clones from patients with recurrent herpes labialis. The Journal of General Virology. 66: 249-58. PMID 2981967 DOI: 10.1099/0022-1317-66-2-249 |
0.35 |
|
| 1985 |
Rice GP, Woelfel EL, Talbot PJ, Braheny SL, Sipe JC, Knobler RL, Merigan TC, Oldstone MB. Immunological complications in multiple sclerosis patients receiving interferon. Annals of Neurology. 18: 439-42. PMID 2416266 DOI: 10.1002/Ana.410180405 |
0.342 |
|
| 1985 |
Panitch HS, Francis GS, Hooper CJ, Merigan TC, Johnson KP. Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon. Annals of Neurology. 18: 434-8. PMID 2416265 DOI: 10.1002/Ana.410180404 |
0.34 |
|
| 1985 |
Rasmussen L, Mullenax J, Nelson R, Merigan TC. Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. Journal of Virology. 55: 274-80. PMID 2410626 DOI: 10.1128/Jvi.55.2.274-280.1985 |
0.311 |
|
| 1984 |
Quesada JR, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, Adams F, Gutterman JU. Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma The American Journal of Medicine. 77: 427-432. PMID 6548079 DOI: 10.1016/0002-9343(84)90097-4 |
0.302 |
|
| 1984 |
Basham TY, Smith WK, Merigan TC. Interferon enhances antibody-dependent cellular cytotoxicity when suboptimal concentrations of antibody are used. Cellular Immunology. 88: 393-400. PMID 6435886 DOI: 10.1016/0008-8749(84)90172-2 |
0.305 |
|
| 1984 |
Knobler RL, Panitch HS, Braheny SL, Sipe JC, Rice GPA, Huddlestone JR, Francis GS, Hooper CJ, Kamin-Lewis RM, Johnson KP, Oldstone MBA, Merigan TC. Systemic alpha-interferon therapy of multiple sclerosis Neurology. 34: 1273-1279. PMID 6384817 DOI: 10.1212/Wnl.34.10.1273 |
0.31 |
|
| 1984 |
Kamin-Lewis RM, Panitch HS, Merigan TC, Johnson KP. Decreased interferon synthesis and responsiveness to interferon by leukocytes from multiple sclerosis patients given natural alpha interferon. Journal of Interferon Research. 4: 423-32. PMID 6333472 DOI: 10.1089/Jir.1984.4.423 |
0.321 |
|
| 1984 |
Chou SW, Dylewski JS, Gaynon MW, Egbert PR, Merigan TC. Alpha-interferon administration in cytomegalovirus retinitis. Antimicrobial Agents and Chemotherapy. 25: 25-8. PMID 6322678 DOI: 10.1128/Aac.25.1.25 |
0.315 |
|
| 1984 |
Merigan TC, Baer GM, Winkler WG, Bernard KW, Gibert CG, Chany C, Veronesi R. Human leukocyte interferon administration to patients with symptomatic and suspected rabies. Annals of Neurology. 16: 82-7. PMID 6205625 DOI: 10.1002/Ana.410160116 |
0.355 |
|
| 1984 |
Rasmussen LE, Nelson RM, Kelsall DC, Merigan TC. Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proceedings of the National Academy of Sciences of the United States of America. 81: 876-80. PMID 6199788 DOI: 10.1073/Pnas.81.3.876 |
0.321 |
|
| 1984 |
Rasmussen L, Chen PT, Mullenax JG, Merigan TC. Inhibition of human cytomegalovirus replication by 9-(1,3-dihydroxy-2-propoxymethyl)guanine alone and in combination with human interferons. Antimicrobial Agents and Chemotherapy. 26: 441-5. PMID 6097163 DOI: 10.1128/Aac.26.4.441 |
0.361 |
|
| 1984 |
Merigan TC. What are we going to do about AIDS and HTLV-III/LAV infection? The New England Journal of Medicine. 311: 1311-3. PMID 6092955 DOI: 10.1056/Nejm198411153112009 |
0.342 |
|
| 1983 |
Creasey AA, Eppstein DA, Marsh YV, Khan Z, Merigan TC. Growth regulation of melanoma cells by interferon and (2'-5')oligoadenylate synthetase. Molecular and Cellular Biology. 3: 780-6. PMID 6865941 DOI: 10.1128/Mcb.3.5.780 |
0.302 |
|
| 1983 |
Rice GP, Casali P, Merigan TC, Oldstone MB. Natural killer cell activity in patients with multiple sclerosis given alpha interferon. Annals of Neurology. 14: 333-8. PMID 6638954 DOI: 10.1002/Ana.410140312 |
0.352 |
|
| 1983 |
Smith CI, Weissberg J, Bernhardt L, Gregory PB, Robinson WS, Merigan TC. Acute Dane particle suppression with recombinant leukocyte A interferon in chronic hepatitis B virus infection. The Journal of Infectious Diseases. 148: 907-13. PMID 6631076 DOI: 10.1093/Infdis/148.5.907 |
0.37 |
|
| 1983 |
Preiksaitis JK, Rosno S, Grumet C, Merigan TC. Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy. The Journal of Infectious Diseases. 147: 974-81. PMID 6304206 DOI: 10.1093/Infdis/147.6.974 |
0.328 |
|
| 1983 |
Chou S, Merigan TC. Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. The New England Journal of Medicine. 308: 921-5. PMID 6300675 DOI: 10.1056/Nejm198304213081603 |
0.311 |
|
| 1983 |
Arvin AM, Martin DP, Gard EA, Merigan TC. Interferon prophylaxis against simian varicella in Erythrocebus patas monkeys. The Journal of Infectious Diseases. 147: 149-54. PMID 6296238 DOI: 10.1093/Infdis/147.1.149 |
0.323 |
|
| 1982 |
Pazin GJ, Ho M, Haverkos HW, Armstrong JA, Breinig MC, Wechsler HL, Arvin A, Merigan TC, Cantell K. Effects of interferon-alpha on human warts. Journal of Interferon Research. 2: 235-43. PMID 7119508 DOI: 10.1089/Jir.1982.2.235 |
0.328 |
|
| 1982 |
Smith CI, Scullard GH, Gregory PB, Robinson WS, Merigan TC. Preliminary studies of acyclovir in chronic hepatitis B. The American Journal of Medicine. 73: 267-70. PMID 7102705 DOI: 10.1016/0002-9343(82)90103-6 |
0.327 |
|
| 1982 |
Sacks SL, Merigan TC, Kaminska J, Fox IH. Inactivation of S-adenosylhomocysteine hydrolase during adenine arabinoside therapy. The Journal of Clinical Investigation. 69: 226-30. PMID 7054240 DOI: 10.1172/Jci110434 |
0.318 |
|
| 1982 |
Pollard RB, Arvin AM, Gamberg P, Rand KH, Gallagher JG, Merigan TC. Specific cell-mediated immunity and infections with herpes viruses in cardiac transplant recipients. The American Journal of Medicine. 73: 679-87. PMID 6291387 DOI: 10.1016/0002-9343(82)90410-7 |
0.37 |
|
| 1982 |
Winston DJ, Ho WG, Rasmussen LE, Lin CH, Chu HL, Merigan TC, Gale RP. Use of intravenous immune globulin in patients receiving bone marrow transplants. Journal of Clinical Immunology. 2: 42S-47S. PMID 6282926 DOI: 10.1007/Bf00918366 |
0.313 |
|
| 1982 |
Rasmussen L, Kelsall D, Nelson R, Carney W, Hirsch M, Winston D, Preiksaitis J, Merigan TC. Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus. The Journal of Infectious Diseases. 145: 191-9. PMID 6274969 DOI: 10.1093/Infdis/145.2.191 |
0.336 |
|
| 1982 |
Merigan TC. Interferons as antivirals in man. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 299: 109-12. PMID 6183684 DOI: 10.1098/Rstb.1982.0110 |
0.397 |
|
| 1982 |
Merigan TC. Interferon-the first quarter century. Jama. 248: 2513-6. PMID 6182308 DOI: 10.1001/Jama.1982.03330190067040 |
0.305 |
|
| 1982 |
Preiksaitis JK, Rosno S, Rasmussen L, Merigan TC. Cytomegalovirus infection in heart transplant recipients: preliminary results of a controlled trial of intravenous gamma globulin. Journal of Clinical Immunology. 2: 36S-41S. PMID 6177709 DOI: 10.1007/Bf00918365 |
0.323 |
|
| 1982 |
Sacks SL, Scullard GH, Pollard RB, Gregory PB, Robinson WS, Merigan TC. Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination. Antimicrobial Agents and Chemotherapy. 21: 93-100. PMID 6177285 DOI: 10.1128/Aac.21.1.93 |
0.392 |
|
| 1982 |
Smith CI, Kitchen LW, Scullard GH, Robinson WS, Gregory PB, Merigan TC. Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis B infection. Jama. 247: 2261-5. PMID 6175774 DOI: 10.1001/Jama.1982.03320410043029 |
0.366 |
|
| 1982 |
Horning SJ, Levine JF, Miller RA, Rosenberg SA, Merigan TC. Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. Jama. 247: 1718-22. PMID 6174742 DOI: 10.1001/Jama.1982.03320370032025 |
0.302 |
|
| 1982 |
Scullard GH, Greenberg HB, Smith JL, Gregory PB, Merigan TC, Robinson WS. Antiviral treatment of chronic hepatitis B virus infection: infectious virus cannot be detected in patient serum after permanent responses to treatment. Hepatology (Baltimore, Md.). 2: 39-49. PMID 6172352 DOI: 10.1002/Hep.1840020107 |
0.376 |
|
| 1982 |
Stiehm ER, Kronenberg LH, Rosenblatt HM, Bryson Y, Merigan TC. UCLA conference. Interferon: immunobiology and clinical significance. Annals of Internal Medicine. 96: 80-93. PMID 6172066 DOI: 10.7326/0003-4819-96-1-80 |
0.346 |
|
| 1981 |
Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology. 81: 987-91. PMID 7286593 DOI: 10.1016/S0016-5085(81)80002-9 |
0.336 |
|
| 1981 |
Merigan TC. Virology and immune mechanisms. Cancer. 47: 1091-4. PMID 6263441 DOI: 10.1002/1097-0142(19810301)47:5+<1091::Aid-Cncr2820471306>3.0.Co;2-# |
0.361 |
|
| 1981 |
Scullard GH, Andres LL, Greenberg HB, Smith JL, Sawhney VK, Neal EA, Mahal AS, Popper H, Merigan TC, Robinson WS, Gregory PB. Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside. Hepatology (Baltimore, Md.). 1: 228-32. PMID 6169615 DOI: 10.1002/Hep.1840010306 |
0.338 |
|
| 1981 |
Louie AC, Gallagher JG, Sikora K, Levy R, Rosenberg SA, Merigan TC. Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. Blood. 58: 712-8. PMID 6168319 DOI: 10.1182/Blood.V58.4.712.712 |
0.317 |
|
| 1981 |
Stewart GJ, Kelsall BL, Charron DJ, Grumet FC, Merigan TC. The role of HLA-DR determinants in monocyte-macrophage presentation of herpes simplex virus antigen to human T cells. Cellular Immunology. 61: 11-21. PMID 6167367 DOI: 10.1016/0008-8749(81)90349-X |
0.327 |
|
| 1981 |
Scullard GH, Pollard RB, Smith JL, Sacks SL, Gregory PB, Robinson WS, Merigan TC. Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. The Journal of Infectious Diseases. 143: 772-83. PMID 6166691 DOI: 10.1093/Infdis/143.6.772 |
0.368 |
|
| 1981 |
Merigan TC, Gallagher JG, Pollard RB, Arvin AM. Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer. Antimicrobial Agents and Chemotherapy. 19: 193-5. PMID 6166245 DOI: 10.1128/Aac.19.1.193 |
0.337 |
|
| 1981 |
Sonnenfeld G, Meruelo D, McDevitt HO, Merigan TC. Effect of type I and type II interferons on murine thymocyte surface antigen expression: induction or selection? Cellular Immunology. 57: 427-39. PMID 6163553 DOI: 10.1016/0008-8749(81)90101-5 |
0.316 |
|
| 1981 |
Chou S, Gallagher JG, Merigan TC. Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. Lancet (London, England). 1: 1392-4. PMID 6113353 DOI: 10.1016/S0140-6736(81)92570-8 |
0.337 |
|
| 1980 |
Pollard RB, Egbert PR, Gallagher JG, Merigan TC. Cytomegalovirus retinitis in immunosuppressed hosts. I. Natural history and effects of treatment with adenine arabinoside. Annals of Internal Medicine. 93: 655-64. PMID 6259979 DOI: 10.7326/0003-4819-93-5-655 |
0.349 |
|
| 1980 |
Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. The Journal of Clinical Investigation. 65: 869-78. PMID 6244336 DOI: 10.1172/Jci109739 |
0.396 |
|
| 1980 |
Rasmussen L, Merigan TC. Effect of interferon therapy on circulating lymphocytes in humans. Journal of Interferon Research. 1: 101-10. PMID 6180033 DOI: 10.1089/Jir.1980.1.101 |
0.364 |
|
| 1980 |
Sikora K, Dilley J, Basham T, Levy R, Merigan T. Inhibition Of Lymphoma Hybrids By Human Interferon The Lancet. 316: 891-893. PMID 6159511 DOI: 10.1016/S0140-6736(80)92050-4 |
0.327 |
|
| 1980 |
Stevens DA, Merigan TC. Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. A randomized trial. Archives of Internal Medicine. 140: 52-4. PMID 6153260 DOI: 10.1001/Archinte.1980.00330130054016 |
0.372 |
|
| 1979 |
Sacks SL, Smith JL, Pollard RB, Sawhney V, Mahol AS, Gregory P, Merigan TC, Robinson WS. Toxicity of vidarabine. Jama. 241: 28-9. PMID 758490 DOI: 10.1001/Jama.1979.03290270020010 |
0.317 |
|
| 1979 |
Merigan TC. Human interferon as a therapeutic agent. The New England Journal of Medicine. 300: 42-3. PMID 758162 DOI: 10.1056/Nejm197901043000113 |
0.302 |
|
| 1979 |
Hafkin B, Pollard RB, Tiku ML, Robinson WS, Merigan TC. Effects of interferon and adenine arabinoside treatment of hepatitis B virus infection on cellular immune responses. Antimicrobial Agents and Chemotherapy. 16: 781-7. PMID 533259 DOI: 10.1128/Aac.16.6.781 |
0.378 |
|
| 1979 |
Huddlestone JR, Merigan TC, Oldstone MB. Induction and kinetics of natural killer cells in humans following interferon therapy. Nature. 282: 417-9. PMID 503223 DOI: 10.1038/282417A0 |
0.349 |
|
| 1979 |
Gallagher JG, Merigan TC. Prolonged herpes-zoster infection associated with immunosuppressive therapy. Annals of Internal Medicine. 91: 842-6. PMID 391116 DOI: 10.7326/0003-4819-91-6-842 |
0.301 |
|
| 1979 |
Sonnenfeld G, Merigan TC. The role of interferon in viral infections Springer Seminars in Immunopathology. 2: 311-338. DOI: 10.1007/Bf00198722 |
0.382 |
|
| 1978 |
Pollard RB, Smith JL, Neal A, Gregory PB, Merigan TC, Robinson WS. Effect of vidarabine on chronic hepatitis B virus infection. Jama. 239: 1648-50. PMID 633577 DOI: 10.1001/Jama.1978.03280430064020 |
0.382 |
|
| 1978 |
Sonnenfeld G, Mandel AD, Merigan TC. Time and dosage dependence of immunoenhancement by murine type II interferon preparations. Cellular Immunology. 40: 285-93. PMID 363280 DOI: 10.1016/0008-8749(78)90336-2 |
0.316 |
|
| 1978 |
Merigan TC, Sikora K, Breeden JH, Levy R, Rosenberg SA. Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. The New England Journal of Medicine. 299: 1449-53. PMID 362211 DOI: 10.1056/Nejm197812282992608 |
0.31 |
|
| 1978 |
Merigan TC, Rand KH, Pollard RB, Abdallah PS, Jordan GW, Fried RP. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. The New England Journal of Medicine. 298: 981-7. PMID 347294 DOI: 10.1056/Nejm197805042981801 |
0.359 |
|
| 1978 |
Rasmussen L, Merigan TC. Role of T lymphocytes in cellular immune responses during herpes simplex virus infection in humans. Proceedings of the National Academy of Sciences of the United States of America. 75: 3957-61. PMID 308659 DOI: 10.1073/Pnas.75.8.3957 |
0.354 |
|
| 1978 |
Rand KH, Merigan TC. Cytomegalovirus: a not so innocent bystander. Jama. 240: 2470-1. PMID 213621 DOI: 10.1001/Jama.1978.03290220082028 |
0.316 |
|
| 1978 |
Pollard RB, Rand KH, Arvin AM, Merigan TC. Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. The Journal of Infectious Diseases. 137: 541-9. PMID 207783 DOI: 10.1093/Infdis/137.5.541 |
0.342 |
|
| 1978 |
Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. The Journal of Infectious Diseases. 137: 531-40. PMID 207782 DOI: 10.1093/Infdis/137.5.531 |
0.37 |
|
| 1978 |
Holmes AR, Rasmussen L, Merigan TC. Factors affecting the interferon sensitivity of human cytomegalovirus. Intervirology. 9: 48-55. PMID 202571 DOI: 10.1159/000148920 |
0.374 |
|
| 1977 |
Sonnenfeld G, Mandel AD, Merigan TC. The immunosuppressive effect of type II mouse interferon preparations on antibody production. Cellular Immunology. 34: 193-206. PMID 338162 DOI: 10.1016/0008-8749(77)90243-X |
0.312 |
|
| 1977 |
Merigan TC, Oldstone MBA, Welsh RM. Interferon production during lymphocytic choriomeningitis virus infection of nude and normal mice Nature. 268: 67-68. PMID 301989 DOI: 10.1038/268067A0 |
0.37 |
|
| 1977 |
Rand KH, Johnson KP, Rubinstein LJ, Wolinsky JS, Penney JB, Walker DL, Padgett BL, Merigan TC. Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: use of virus-containing cells in the urine to assess response to therapy. Annals of Neurology. 1: 458-62. PMID 214020 DOI: 10.1002/Ana.410010509 |
0.363 |
|
| 1977 |
Rasmussen L, Holmes AR, Hofmeister B, Merigan TC. Multiplicity-dependent Replication of Varicella-zoster Virus in Interferon-treated Cells Journal of General Virology. 35: 361-368. PMID 195010 DOI: 10.1099/0022-1317-35-2-361 |
0.391 |
|
| 1977 |
Rand KH, Rasmussen LE, Pollard RB, Arvin A, Merigan TC. Cellular immunity and herpesvirus infections in cardiac transplant patients New England Journal of Medicine. 296: 1372-1377. PMID 193008 DOI: 10.1056/Nejm197706162962402 |
0.386 |
|
| 1976 |
Rasmussen L, Haahr S, Merigan TC. Cellular immunity to herpes simplex infection in humans. Survey of Ophthalmology. 21: 191-193. PMID 1086514 DOI: 10.1016/0039-6257(76)90099-0 |
0.34 |
|
| 1976 |
Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis New England Journal of Medicine. 295: 517-522. PMID 950957 DOI: 10.1056/Nejm197609022951001 |
0.348 |
|
| 1976 |
Wiktor TJ, Koprowski H, Mitchell JR, Merigan TC. Role of interferon in prophylaxis of rabies after exposure. The Journal of Infectious Diseases. A260-5. PMID 819599 DOI: 10.1093/Infdis/133.Supplement_2.A260 |
0.311 |
|
| 1976 |
Merigan TC. Efficacy of Adenine Arabinoside in Herpes Zoster The New England Journal of Medicine. 294: 1233-1234. PMID 772429 DOI: 10.1056/Nejm197605272942212 |
0.331 |
|
| 1976 |
Haahr S, Rasmussen L, Merigan TC. Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus. Infection and Immunity. 14: 47-54. PMID 181328 DOI: 10.1128/Iai.14.1.47-54.1976 |
0.352 |
|
| 1975 |
Stevens DA, Ferrington RA, Jordan GW, Merigan TC. Cellular events in zoster vesicles: relation to clinical course and immune parameters. The Journal of Infectious Diseases. 131: 509-15. PMID 165243 DOI: 10.1093/Infdis/131.5.509 |
0.336 |
|
| 1974 |
Black DR, Eckstein F, DeClercq E, Merigan TC. Studies on the toxicity and antiviral activity of various polynucleotides. Antimicrobial Agents and Chemotherapy. 3: 198-206. PMID 4790587 DOI: 10.1128/Aac.3.2.198 |
0.301 |
|
| 1974 |
Jordan GW, Fried RP, Merigan TC. Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating, antiviral activity, and host responses to infection. The Journal of Infectious Diseases. 130: 56-62. PMID 4601181 DOI: 10.1093/Infdis/130.1.56 |
0.394 |
|
| 1974 |
Jordan GW, Merigan TC. Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses. The Journal of Infectious Diseases. 130: 495-501. PMID 4370611 DOI: 10.1093/Infdis/130.5.495 |
0.373 |
|
| 1974 |
Rodgers R, Merigan TC. Interferon production by individual cells. Virology. 57: 467-474. PMID 4361456 DOI: 10.1016/0042-6822(74)90186-X |
0.304 |
|
| 1974 |
Denman AM, Rager-Zisman B, Merigan TC, Tyrrell DAJ. Replication or inactivation of different viruses by human lymphocyte preparations. Infection and Immunity. 9: 373-376. PMID 4361296 DOI: 10.1128/Iai.9.2.373-376.1974 |
0.372 |
|
| 1974 |
Merigan TC. Host Defenses against Viral Disease The New England Journal of Medicine. 290: 323-329. PMID 4358448 DOI: 10.1056/Nejm197402072900608 |
0.343 |
|
| 1973 |
Portnoy J, Bloom K, Merigan TC. The effect of bursectomy and thymectomy on the course of avian influenza virus infection Cellular Immunology. 9: 251-262. PMID 4752847 DOI: 10.1016/0008-8749(73)90076-2 |
0.376 |
|
| 1973 |
Stevens DA, Jordan GW, Waddell TF, Merigan TC. Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. The New England Journal of Medicine. 289: 873-8. PMID 4354007 DOI: 10.1056/Nejm197310252891701 |
0.315 |
|
| 1973 |
Black DR, Connell CJ, Merigan TC. Structure and infectivity of picornaviral RNA encapsidated by cowpea chlorotic mottle virus protein. Journal of Virology. 12: 1209-1215. PMID 4128376 DOI: 10.1128/Jvi.12.6.1209-1215.1973 |
0.331 |
|
| 1973 |
Rager-Zisman B, Merigan TC. A Useful Quantitative Semimicromethod for Viral Plaque Assay Experimental Biology and Medicine. 142: 1174-1179. PMID 4121080 DOI: 10.3181/00379727-142-37202 |
0.341 |
|
| 1972 |
Stevens DA, Merigan TC. Interferon, antibody, and other host factors in herpes zoster Journal of Clinical Investigation. 51: 1170-1178. PMID 5020430 DOI: 10.1172/Jci106910 |
0.338 |
|
| 1972 |
Epstein LB, Stevens DA, Merigan TC. Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination. Proceedings of the National Academy of Sciences of the United States of America. 69: 2632-2636. PMID 4506785 DOI: 10.1073/Pnas.69.9.2632 |
0.365 |
|
| 1972 |
Rogers R, Merigan TC, Hardy WD, Old LJ, Kassel R. Cat interferon inhibits feline leukaemia virus infection in cell culture Nature: New Biology. 237: 270-271. PMID 4504461 DOI: 10.1038/Newbio237270A0 |
0.374 |
|
| 1972 |
Nyhan WL, Shirkey HC, Stevens DA, Merigan TC. Uncertain role of cytosine arabinoside in varicella infection of compromised hosts The Journal of Pediatrics. 81: 562-565. PMID 4340436 DOI: 10.1016/S0022-3476(72)80192-6 |
0.347 |
|
| 1972 |
Goffinet DR, Glatstein EJ, Merigan TC. Herpes Zoster-Varicella Infections and Lymphoma Annals of Internal Medicine. 76: 235-240. PMID 4333227 DOI: 10.7326/0003-4819-76-2-235 |
0.308 |
|
| 1971 |
Epstein LB, Cline MJ, Merigan TC. The interaction of human macrophages and lymphocytes in the phytohemagglutinin-stimulated production of interferon. Journal of Clinical Investigation. 50: 744-753. PMID 16695958 DOI: 10.1172/Jci106545 |
0.32 |
|
| 1971 |
Wong KT, Robinson WS, Merigan TC. Inhibition of rubella virus-specific RNA synthesis by interferon. Experimental Biology and Medicine. 136: 615-618. PMID 5544507 DOI: 10.3181/00379727-136-35324 |
0.331 |
|
| 1971 |
Leavitt TJ, Merigan TC, Freeman JM. Hemolytic-Uremic-Like Syndrome Following Polycarboxylate Interferon Induction: Treatment of Dawson's Inclusion-Body Encephalitis Jama Pediatrics. 121: 43-47. PMID 5539813 DOI: 10.1001/Archpedi.1971.02100120079010 |
0.329 |
|
| 1971 |
Portnoy J, Merigan TC. The Effect of Interferon and Interferon Inducers on Avian Influenza The Journal of Infectious Diseases. 124: 545-552. PMID 5166655 DOI: 10.1093/Infdis/124.6.545 |
0.356 |
|
| 1971 |
Armstrong RW, Merigan TC. Varicella zoster virus: interferon production and comparative interferon sensitivity in human cell cultures. Journal of General Virology. 12: 53-54. PMID 4329449 DOI: 10.1099/0022-1317-12-1-53 |
0.387 |
|
| 1971 |
Clercq Ed, Merigan TC. Thermal activation of the antiviral activity of synthetic polyribonucleotides: influence of DEAE-dextran in various cell cultures Journal of General Virology. 10: 125-130. PMID 4324254 DOI: 10.1099/0022-1317-10-2-125 |
0.349 |
|
| 1970 |
Merigan TC, Clercq ED, Bausek GH. Nonviral interferon inducers The Journal of General Physiology. 56: 57-75. PMID 19873675 DOI: 10.1085/Jgp.56.1.57 |
0.315 |
|
| 1970 |
De Clercq E, Nuwer MR, Merigan TC. Potentiating Effect of Freund's Adjuvant on Interferon Production by Endotoxin or Poly rI*Poly rC. Infection and Immunity. 2: 69-76. PMID 16557802 DOI: 10.1128/Iai.2.1.69-76.1970 |
0.314 |
|
| 1970 |
Merigan TC. Interferon stimulated by double stranded RNA. Nature. 228: 219-222. PMID 5479520 DOI: 10.1038/228219A0 |
0.34 |
|
| 1970 |
Remington JS, Merigan TC. Synthetic Polyanions protect Mice against Intracellular Bacterial Infection Nature. 226: 361-363. PMID 5439736 DOI: 10.1038/226361A0 |
0.32 |
|
| 1970 |
Bausek GH, Merigan TC. Simultaneous Viral and Non-Viral Interferon Production in Human Cell Cultures Experimental Biology and Medicine. 133: 982-985. PMID 5435593 DOI: 10.3181/00379727-133-34609 |
0.367 |
|
| 1970 |
Clercq ED, Merigan TC. Current concepts of interferon and interferon induction Annual Review of Medicine. 21: 17-46. PMID 4912475 DOI: 10.1146/Annurev.Me.21.020170.000313 |
0.377 |
|
| 1970 |
Richman DD, Wong KT, Robinson WS, Merigan TC. Effect of interferon on the replication of Sendai virus Journal of General Virology. 9: 141-150. PMID 4320690 DOI: 10.1099/0022-1317-9-2-141 |
0.34 |
|
| 1970 |
Armstrong RW, Gurwith MJ, Waddell D, Merigan TC. Cutaneous interferon production in patients with Hodgkin's disease and other cancers infected with varicella or vaccinia. The New England Journal of Medicine. 283: 1182-1187. PMID 4319626 DOI: 10.1056/Nejm197011262832202 |
0.363 |
|
| 1970 |
De Clercq E, Nuwer MR, Merigan TC. The role of interferon in the protective effect of a synthetic double-stranded polyribonucleotide against intranasal vesicular stomatitis virus challenge in mice. The Journal of Clinical Investigation. 49: 1565-77. PMID 4317283 DOI: 10.1172/Jci106374 |
0.325 |
|
| 1970 |
De Clercq E, Wells RD, Merigan TC. Increase in Antiviral Activity of Polynucleotides by Thermal Activation Nature. 226: 364-366. PMID 4314782 DOI: 10.1038/226364A0 |
0.316 |
|
| 1970 |
Clercq ED, Merigan TC. Induction of interferon by nonviral agents Jama Internal Medicine. 126: 94-108. DOI: 10.1001/Archinte.1970.00310070096009 |
0.336 |
|
| 1970 |
Merigan TC. Symposium on Interferon and Host Response to Virus Infection Jama Internal Medicine. 126: 49-50. DOI: 10.1001/Archinte.1970.00310070051003 |
0.325 |
|
| 1969 |
Wong KT, Robinson WS, Merigan TC. Synthesis of Viral-Specific Ribonucleic Acid in Rubella Virus-Infected Cells Journal of Virology. 4: 901-903. PMID 16789124 DOI: 10.1128/Jvi.4.6.901-903.1969 |
0.355 |
|
| 1969 |
Guttman PH, Davis WC, Fudenberg HH, Merigan TC. Effect of interferon on the course of spontaneous and radiation-induced renal lesions in the RF-Un mouse. Vox Sanguinis. 17: 279-288. PMID 5262182 DOI: 10.1111/J.1423-0410.1969.Tb00397.X |
0.31 |
|
| 1969 |
Remington JS, Merigan TC. Resistance to Virus Challenge in Mice Infected with Protozoa or Bacteria Experimental Biology and Medicine. 131: 1184-1188. PMID 4309474 DOI: 10.3181/00379727-131-34066 |
0.339 |
|
| 1969 |
Clercq ED, Merigan TC. Requirement of a stable secondary structure for the antiviral activity of polynucleotides. Nature. 222: 1148-1152. PMID 4307027 DOI: 10.1038/2221148A0 |
0.341 |
|
| 1969 |
Clercq ED, Merigan TC. Local and systemic protection by synthetic polyanionic interferon inducers in mice against intranasal, vesicular stomatitis virus. Journal of General Virology. 5: 359-368. DOI: 10.1099/0022-1317-5-3-359 |
0.368 |
|
| 1969 |
Merigan TC. Interferon and Interferon Inducers: The Clinical Outlook Hospital Practice. 4: 42-49. DOI: 10.1080/21548331.1969.11705668 |
0.302 |
|
| 1968 |
Finkelstein MS, Bausek GH, Merigan TC. Interferon Inducers in vitro: Difference in Sensitivity to Inhibitors of RNA and Protein Synthesis Science. 161: 465-467. PMID 5659681 DOI: 10.1126/Science.161.3840.465 |
0.307 |
|
| 1968 |
Waddell DJ, Wilbur JR, Merigan TC. Interferon production in human mumps infections. Experimental Biology and Medicine. 127: 320-324. PMID 5644658 DOI: 10.3181/00379727-127-32681 |
0.329 |
|
| 1968 |
Remington JS, Merigan TC. Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science. 161: 804-806. PMID 4298747 DOI: 10.1126/Science.161.3843.804 |
0.356 |
|
| 1968 |
Merigan TC, Finkelstein MS. Interferon-stimulating and in vivo antiviral effects of various synthetic anionic polymers. Virology. 35: 363-374. PMID 4298648 DOI: 10.1016/0042-6822(68)90215-8 |
0.325 |
|
| 1967 |
Glasgow LA, Hhanshaw JB, Merigan TC, Petralli JK. Interferon and cytomegalovirus in vivo and in vitro. Experimental Biology and Medicine. 125: 843-849. PMID 15938281 DOI: 10.3181/00379727-125-32220 |
0.376 |
|
| 1967 |
Merigan TC, Regelson W. Interferon induction in man by a synthetic polyanion of defined composition. The New England Journal of Medicine. 277: 1283-1287. PMID 6073272 DOI: 10.1056/Nejm196712142772403 |
0.372 |
|
| 1967 |
Merigan TC. Induction of Circulating Interferon by Synthetic Anionic Polymers of Known Composition Nature. 214: 416-417. PMID 6032855 DOI: 10.1038/214416A0 |
0.338 |
|
| 1966 |
Hanna L, Merigan TC, Jawetz E. Inhibition of TRIC agents by virus-induced interferon. Experimental Biology and Medicine. 122: 417-421. PMID 5980548 DOI: 10.3181/00379727-122-31150 |
0.322 |
|
| 1966 |
Merigan TC, Gregory DF, Petralli JK. Physical properties of human interferon prepared in vitro and in vivo. Virology. 29: 515-522. PMID 5945709 DOI: 10.1016/0042-6822(66)90276-5 |
0.324 |
|
| 1966 |
Merigan TC, Hanna L. Characteristics of interferon induced in vitro and in vivo by a TRIC agent. Experimental Biology and Medicine. 122: 421-424. PMID 4292459 DOI: 10.3181/00379727-122-31151 |
0.352 |
|
| 1965 |
Petralli JK, Merigan TC, Wilbur JR. Circulating Interferon after Measles Vaccination The New England Journal of Medicine. 273: 198-201. PMID 14306336 DOI: 10.1056/Nejm196507222730405 |
0.378 |
|
| 1965 |
Merigan TC, Winget CA, Dixon CB. Purification and characterization of vertebrate interferons Journal of Molecular Biology. 13. DOI: 10.1016/S0022-2836(65)80135-8 |
0.327 |
|
| 1964 |
Merigan TC. Purified Interferons: Physical Properties and Species Specificity Science. 145: 811-813. PMID 14163319 DOI: 10.1126/Science.145.3634.811-A |
0.307 |
|
| Show low-probability matches. |